AACR 2020

Presentations

Enfortumab Vedotin | Urothelial Cancer | Abstract 5581/14

Enfortumab vedotin, an anti-Nectin-4 ADC demonstrates bystander cell killing and immunogenic cell death anti-tumor activity mechanisms of action in urothelial cancers